• D A Godoy, P Panhke, P D Guerrero Suarez, and F Murillo-Cabezas.
• Unidad de Cuidados Neurointensivos, Sanatorio Pasteur, Catamarca, Argentina; Unidad de Terapia Intensiva, Hospital San Juan Bautista, Catamarca, Argentina. Electronic address: dagodoytorres@yahoo.com.ar.
• Med Intensiva. 2019 Jan 1; 43 (1): 35-43.

AbstractParoxysmal sympathetic hyperactivity (PSH) is a potentially life-threatening neurological emergency secondary to multiple acute acquired brain injuries. It is clinically characterized by the cyclic and simultaneous appearance of signs and symptoms secondary to exacerbated sympathetic discharge. The diagnosis is based on the clinical findings, and high alert rates are required. No widely available and validated homogeneous diagnostic criteria have been established to date. There have been recent consensus attempts to shed light on this obscure phenomenon. Its physiopathology is complex and has not been fully clarified. However, the excitation-inhibition model is the theory that best explains the different aspects of this condition, including the response to treatment with the available drugs. The key therapeutic references are the early recognition of the disorder, avoiding secondary injuries and the triggering of paroxysms. Once sympathetic crises occur, they must peremptorily aborted and prevented. of the later the syndrome is recognized, the poorer the patient outcome.Copyright © 2017 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

27 keywords...

hide…